超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

上海非利加實業(yè)有限公司Logo

熱門詞: 進(jìn)口電動溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動高溫調(diào)節(jié)閥-德國進(jìn)口電動高溫法蘭調(diào)節(jié)閥進(jìn)口電動蒸汽調(diào)節(jié)閥-德國進(jìn)口電動蒸汽調(diào)節(jié)閥

當(dāng)前位置: 首頁 > 所有品牌 > Isis
Isis
Isis Isis

美國Isis Pharmaceuticals, Inc.
位于美國加州CarIsbad的Isis制藥公司是全球反義藥物研究領(lǐng)域的領(lǐng)先公司.美國Isis制藥公司(Isis公司98年生產(chǎn)全球第一個反義核酸藥物)完成世界最大的反義核酸合成, 一次反義核酸合成量達(dá)到4KG.(600mMol)

Isis Pharmaceuticals, Inc. is a leading drug discovery and development company, focused exclusively on the therapeutic target, RNA. Founded in 1989, Isis' mission is to develop products from its RNA-based technologies, such as antisense. Very little was known about antisense when the Company was first established, but its founders envisioned an opportunity to revolutionize the pharmaceutical industry with a more efficient and targeted means of drug discovery. Since then, Isis scientists have made tremendous progress advancing the science of antisense, unveiling capabilities that have far exceeded their expectations.

Antisense drugs are the first class of drugs targeted to control expression of genes through interactions with RNA. The goal of antisense drugs is to intervene at the RNA level to prevent the production of proteins involved in disease. Antisense drugs are designed to complement and bind (hybridize) to a segment of messenger RNA (mRNA) to form a duplex. mRNA contains instructions to make proteins, including those proteins involved in disease. The formation of this duplex or two stranded molecule prevents the mRNA from functioning normally and from producing a specific protein. Antisense drugs are designed to interact specifically with the intended mRNA target. This high degree of specificity may make antisense drugs more effective and less toxic than traditional drugs.

In addition to expanding our broad pipeline of antisense drugs, our technology supports therapeutic targeting of non-messenger RNA molecules, including microRNAs. In September 2007, we formed Regulus Therapeutics LLC as a joint venture to focus on the discovery and development of microRNA-based drugs to treat disease.

Beyond antisense, Company scientists have created another technology that exploits their knowledge of RNA. Ibis Biosciences, Inc., a majority-owned subsidiary of Isis, has developed and is commercializing the Ibis T5000 Biosensor System for rapid identification and characterization of organisms.

Isis is capitalizing on its expertise through the following assets:


Antisense Research and Drug Development

Antisense drug discovery and development is the cornerstone of Isis. The Company is the leader in all aspects of antisense technology advancement, including mechanism research, the development of new chemistries, novel formulations and innovative drugs.

Gene functionalization and target validation are the first steps in drug discovery. Gene functionalization is the identification of the role a particular gene plays in disease. Target validation is the determination of a gene’s value as a drug target. The Company uses optimized, target-specific antisense inhibitors to generate this critical information. The resulting insights direct the drug discovery research of Isis.

Isis has a broad antisense pipeline with drugs in all phases of preclinical and clinical development to treat a wide variety of health conditions, including cardiovascular, metabolic, neurodegenerative, ocular and inflammatory diseases, and cancer.

Isis was granted marketing clearance for the world’s first antisense drug, Vitravene? (fomivirsen), in 1998. Vitravene is marketed by Novartis Ophthalmics.

Ibis Biosciences, Inc.

Ibis Biosciences, Inc., a majority-owned subsidiary of Isis Pharmaceuticals, has developed and is commercializing the Ibis T5000? Biosensor System for rapid identification and characterization of infectious agents. The Ibis T5000 is currently intended for research use only and not for use in diagnostic procedures. It is capable of identifying virtually all bacteria, viruses and fungi, and can provide information about drug resistance, virulence and strain type of these pathogens. Commercial applications for the Ibis T5000 Biosensor System include epidemiologic surveillance, monitoring of pandemic diseases, identification of emerging or previously unknown pathogens, forensic characterization of human samples, identification of sources of hospital-associated infections, and, in the future, human infectious disease diagnostics. Ibis develops, manufactures and markets Ibis T5000 instruments and assay kits. Ibis is a product of Isis' innovation and research that has generated more than $70 million in revenue from various government agencies to develop its Ibis T5000 Biosensor System and related assay kits.

At the beginning of 2008, Abbott invested $20 million in Ibis. In July 2008, Abbott invested an additional $20 million in Ibis, bringing Abbott total investment to $40 million. Abbott owns 18.6% of Ibis at a post money valuation of $215 million, with the option to purchase the remaining shares of Ibis by June 30, 2009. Abbott and Ibis have also entered into a distribution relationship under which Abbott will be selling Ibis products.

Regulus Therapeutics LLC

Regulus was established as a joint venture with our partners Alnylam Pharmaceuticals to discover, develop and commercialize microRNA-based therapeutics. Because microRNAs regulate whole networks of genes that can be involved in discrete disease processes, microRNA-based therapeutics represent a new approach to target the pathways of human disease. Regulus combines the strengths and assets of our and Alnylam’s technologies, know-how, and intellectual property relating to microRNA therapeutics.

Intellectual Property

With over 1,500 issued patents worldwide, Isis is the owner of one of the largest antisense and RNA patent estates in the pharmaceutical industry. The Company holds key patents covering antisense mechanisms, biology, chemistry, inhibitors of gene expression and manufacturing of antisense drugs. This patent estate is a valuable asset to the Company and its shareholders, as it protects Isis' inventions in RNA-based drug discovery and encourages revenue-generating partnerships. As of September 30, 2008, Isis has generated more than $118 million from licensing its intellectual property.
?

關(guān)于我們客戶服務(wù)產(chǎn)品分類法律聲明
主站蜘蛛池模板: 欧美性猛交一区二区三区精品 | 久久精品国产三级不卡 | 美女全黄网站 | 久热福利| a集毛片 | 波多野结衣乳巨码无在线观看 | 在线精品福利 | 日韩电影免费在线观看视频 | 91系列在线观看免费 | 日本一区二区三区在线播放 | 亚洲色图日韩精品 | 欧美高清在线精品一区二区不卡 | 日韩色视频一区二区三区亚洲 | 黄色a免费 | 欧美日韩国产综合视频在线看 | 怡红院一区二区三区 | 国产成人综合欧美精品久久 | 国产免费资源高清小视频在线观看 | 国产区视频在线观看 | 日本久热 | 天天曰夜夜曰 | 欧美亚洲国产精品久久久 | 亚洲国产精品婷婷久久久久 | 亚洲国产成人精品区 | 欧美日韩国产亚洲人成 | 亚洲欧洲精品一区二区三区 | 2020精品极品国产色在线观看 | 精品视频一区二区三区四区五区 | 91精品导航| 日韩在线一区二区三区免费视频 | 国内精品视频 | 亚洲欧美视频在线 | 国产成人高清一区二区私人 | 日韩精品一区二区三区视频 | 日韩一区二区免费视频 | 亚洲第一区视频在线观看 | 一区二区三区在线 | 亚洲高清一区二区三区 | 国产精品久久久久久免费播放 | a一区二区三区视频 | 日韩在线小视频 |